泰林生物
(300813)
| 流通市值：12.74亿 | | | 总市值：20.30亿 |
| 流通股本：7605.11万 | | | 总股本：1.21亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 171,228,615.53 | 300,037,604.18 | 381,299,872.13 | 396,982,503.2 |
| 应收票据及应收账款 | 43,636,934.99 | 44,912,332.1 | 30,667,162.32 | 36,082,237.96 |
| 应收账款 | 43,636,934.99 | 44,912,332.1 | 30,667,162.32 | 36,082,237.96 |
| 应收款项融资 | 22,347,340.06 | 12,474,326.71 | 9,521,741.36 | 5,120,699.78 |
| 预付款项 | 7,536,756.56 | 4,308,405.53 | 3,768,661.8 | 4,627,342.88 |
| 其他应收款合计 | 12,433,173.1 | 11,453,251.12 | 9,067,508.64 | 8,945,805.75 |
| 存货 | 159,406,248.73 | 158,909,437.83 | 150,289,218.55 | 160,550,413.98 |
| 合同资产 | 8,248,750.54 | 6,523,664.04 | 6,020,820.05 | 5,775,794.25 |
| 其他流动资产 | 211,484,038.07 | 78,787,124.03 | 19,977,873.73 | 20,665,402.62 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 636,321,857.58 | 617,406,145.54 | 610,612,858.58 | 638,750,200.42 |
| 非流动资产: | | | | |
| 长期股权投资 | 8,000,000 | 8,000,000 | 4,000,000 | 4,000,000 |
| 投资性房地产 | 10,052,324.06 | 10,139,846.24 | 10,133,038.55 | 10,218,154.52 |
| 固定资产 | 258,669,490.39 | 262,740,230.62 | 263,070,540.88 | 264,794,164.8 |
| 在建工程 | 5,838,339.74 | 4,312,333.37 | 3,657,090.84 | 4,265,719.14 |
| 无形资产 | 11,037,386 | 10,998,081.4 | 11,134,650.22 | 11,271,219.28 |
| 长期待摊费用 | 31,656,228.25 | 32,429,566.18 | 33,261,120.09 | 31,847,604.18 |
| 递延所得税资产 | 5,148.15 | 11,554.22 | 901,553.46 | 922,333.49 |
| 其他非流动资产 | 508,300 | 3,607,711 | 7,110,268 | 7,438,512.04 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 325,767,216.59 | 332,239,323.03 | 333,268,262.04 | 334,757,707.45 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 962,089,074.17 | 949,645,468.57 | 943,881,120.62 | 973,507,907.87 |
| 流动负债: | | | | |
| 短期借款 | 15,645,426.7 | 8,250,155.45 | - | - |
| 应付票据及应付账款 | 16,479,055.41 | 15,430,950.9 | 12,127,837.65 | 14,755,160 |
| 其中：应付票据 | - | - | 0 | 202,005 |
| 应付账款 | 16,479,055.41 | 15,430,950.9 | 12,127,837.65 | 14,553,155 |
| 合同负债 | 84,965,135.53 | 85,633,822.94 | 79,794,270.1 | 94,447,073.74 |
| 应付职工薪酬 | 11,884,343.49 | 12,287,099.98 | 11,690,999.56 | 25,661,330.25 |
| 应交税费 | 3,824,019.21 | 2,222,687.86 | 3,405,786.54 | 7,610,689.37 |
| 其他应付款合计 | 6,173,774.26 | 7,510,526.68 | 11,607,213.29 | 14,194,994.83 |
| 其他流动负债 | 2,299,959.13 | 4,230,196.05 | 4,736,883.21 | 5,139,750.91 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 141,271,713.73 | 135,565,439.86 | 123,362,990.35 | 161,808,999.1 |
| 非流动负债: | | | | |
| 应付债券 | 161,581,781.72 | 159,619,546.57 | 160,812,472.2 | 157,589,473.62 |
| 递延所得税负债 | 3,630,938.23 | 3,630,938.23 | 3,870,257.82 | 3,870,257.82 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 165,212,719.95 | 163,250,484.8 | 164,682,730.02 | 161,459,731.44 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 306,484,433.68 | 298,815,924.66 | 288,045,720.37 | 323,268,730.54 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 109,142,103 | 109,138,939 | 108,709,629 | 108,705,025 |
| 其他权益工具 | 67,271,538.3 | 67,288,949.93 | 69,661,016.58 | 69,690,147.58 |
| 资本公积 | 201,822,362.86 | 201,766,734.15 | 194,241,285.36 | 194,161,740.36 |
| 减:库存股 | - | - | 0 | - |
| 其他综合收益 | - | - | 0 | - |
| 专项储备 | - | - | 0 | - |
| 盈余公积 | 27,628,568.73 | 27,628,568.73 | 27,628,568.73 | 27,628,568.73 |
| 一般风险准备 | - | - | 0 | - |
| 未分配利润 | 248,978,604.64 | 244,245,982.92 | 254,450,535.3 | 248,577,454.64 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 654,843,177.53 | 650,069,174.73 | 654,691,034.97 | 648,762,936.31 |
| 少数股东权益 | 761,462.96 | 760,369.18 | 1,144,365.28 | 1,476,241.02 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 655,604,640.49 | 650,829,543.91 | 655,835,400.25 | 650,239,177.33 |
| 负债和股东权益合计 | 962,089,074.17 | 949,645,468.57 | 943,881,120.62 | 973,507,907.87 |
| 公告日期 | 2024-10-30 | 2024-08-29 | 2024-04-24 | 2024-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |